132 related articles for article (PubMed ID: 230303)
1. Anticellular effects of 9-(2-hydroxyethoxymethyl) guanine against herpes simplex virus-transformed cells.
Nishiyama Y; Rapp F
J Gen Virol; 1979 Oct; 45(1):227-30. PubMed ID: 230303
[TBL] [Abstract][Full Text] [Related]
2. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.
Elion GB; Furman PA; Fyfe JA; de Miranda P; Beauchamp L; Schaeffer HJ
Proc Natl Acad Sci U S A; 1977 Dec; 74(12):5716-20. PubMed ID: 202961
[TBL] [Abstract][Full Text] [Related]
3. 9-(2-hydroxyethoxymethyl)guanine as an inhibitor of herpes simplex virus replication.
Centifanto YM; Kaufman HE
Chemotherapy; 1979; 25(5):279-81. PubMed ID: 225135
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Shimizu K; Seno T
Mol Pharmacol; 1987 Sep; 32(3):410-6. PubMed ID: 2823092
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine).
Smith KO; Kennell WL; Poirier RH; Lynd FT
Antimicrob Agents Chemother; 1980 Feb; 17(2):144-50. PubMed ID: 6247967
[TBL] [Abstract][Full Text] [Related]
6. Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on the proliferation of herpes simplex virus type 1-transformed and thymidine kinase-deficient mouse cells.
Bubley G; Crumpacker C; De Clercq E; Schnipper L
Virology; 1983 Sep; 129(2):490-2. PubMed ID: 6312685
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of viruses to phosphorylated 9-(2-hydroxyethoxymethyl)guanine revealed in TK-transformed cells.
Darby G; Larder BA; Bastow KF; Field HJ
J Gen Virol; 1980 Jun; 48(Pt 2):451-4. PubMed ID: 6249891
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds on herpes simplex virus (HSV)-infected cells and HSV thymidine kinase gene-transformed cells.
Balzarini J; De Clercq E
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):379-89. PubMed ID: 2545982
[No Abstract] [Full Text] [Related]
9. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine.
Fyfe JA; Keller PM; Furman PA; Miller RL; Elion GB
J Biol Chem; 1978 Dec; 253(24):8721-7. PubMed ID: 214430
[No Abstract] [Full Text] [Related]
10. Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus.
Field HJ; Darby G; Wildy P
J Gen Virol; 1980 Jul; 49(1):115-24. PubMed ID: 6252285
[TBL] [Abstract][Full Text] [Related]
11. Suppression of herpes simplex virus type 1 reactivation from latency by (+-)-9-([(Z)-2-(hydroxymethyl)cyclohexyl]methyl) guanine (L-653,180) in vitro.
Nsiah YA; Tolman RL; Karkas JD; Rapp F
Antimicrob Agents Chemother; 1990 Aug; 34(8):1551-5. PubMed ID: 2171423
[TBL] [Abstract][Full Text] [Related]
12. Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.
Schnipper LE; Crumpacker CS
Proc Natl Acad Sci U S A; 1980 Apr; 77(4):2270-3. PubMed ID: 6246532
[TBL] [Abstract][Full Text] [Related]
13. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Seno T
Mol Pharmacol; 1985 Dec; 28(6):581-7. PubMed ID: 3001499
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on interactions of acyclovir with Epstein-Barr and other herpes viruses.
Pagano JS; Datta AK
Am J Med; 1982 Jul; 73(1A):18-26. PubMed ID: 6285710
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
Chen H; Teng L; Li JN; Park R; Mold DE; Gnabre J; Hwu JR; Tseng WN; Huang RC
J Med Chem; 1998 Jul; 41(16):3001-7. PubMed ID: 9685239
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of sensitivity of acyclovir of herpes simplex virus clinical isolates.
McLaren C; Sibrack CD; Barry DW
Am J Med; 1982 Jul; 73(1A):376-9. PubMed ID: 6285726
[TBL] [Abstract][Full Text] [Related]
17. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir.
Crumpacker CS; Schnipper LE; Marlowe SI; Kowalsky PN; Hershey BJ; Levin MJ
N Engl J Med; 1982 Feb; 306(6):343-6. PubMed ID: 6275267
[No Abstract] [Full Text] [Related]
18. Thymidine kinase not required for antiviral activity of acyclovir against mouse cytomegalovirus.
Burns WH; Wingard JR; Bender WJ; Saral R
J Virol; 1981 Sep; 39(3):889-93. PubMed ID: 6270357
[TBL] [Abstract][Full Text] [Related]
19. N2-phenyldeoxyguanosine: a novel selective inhibitor of herpes simplex thymidine kinase.
Focher F; Hildebrand C; Freese S; Ciarrocchi G; Noonan T; Sangalli S; Brown N; Spadari S; Wright G
J Med Chem; 1988 Aug; 31(8):1496-500. PubMed ID: 2840499
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by acyclovir of herpes simplex virus type 2 morphologically transformed cell growth in tissue culture and tumor-bearing animals.
Kucera LS; Furman PA; Elion GB
J Med Virol; 1983; 12(2):119-27. PubMed ID: 6311971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
